Skip to contentpdufa.bio

UTEBZI (tebipenem pivoxil hydrobromide): FDA NDA 215960

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 215960 is the FDA application for UTEBZI (tebipenem pivoxil hydrobromide). The FDA's Orange Book lists the applicant of record as GLAXOSMITHKLINE LLC and the first approval on it as Jun 17, 2026. Code name used in development: SPR994. Owner today: GSK plc (LSE/NYSE: GSK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 215960 · Orange Book NDA 215960

Names for this drug

Brand name (FDA)UTEBZI
Orange Book trade name: UTEBZI
Active ingredient (FDA)TEBIPENEM PIVOXIL HYDROBROMIDE
Code nameSPR994
Source: GSK press release, Sep 22, 2022
“Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994)”

Who holds the application

FDA applicant of recordGLAXOSMITHKLINE LLC
FDA Orange Book data files as of Nov 13, 2026
Owner todayGSK plc (GSK)
Source: GSK press release, Jun 17, 2026
“GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced”
Earlier / partnerSpero Therapeutics (SPRO): licensed the drug to the current owner, Sep 22, 2022
Source: GSK press release, Sep 22, 2022
“GSK plc (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive licence agreement for tebipenem pivoxil hydrobromide (tebipenem HBr)”

Products on NDA 215960 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001UTEBZITABLET;ORALEQ 300MG BASEJun 17, 2026

FDA decisions we track for this drug

Tebipenem HBr (SPR994) - (PIVOT-PO)GSK · DecidedTebipenem HBr (SPR994) - (PIVOT-PO)SPRO · Decided

Drug page: /drug/tebipenem-hbr

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.